Description

Listing and trading permission for 22,44,000 equity shares of DIPNA PHARMACHEM LIMITED issued on preferential basis pursuant to warrant conversion, effective January 20, 2026.

Summary

BSE has listed 22,44,000 new equity shares of DIPNA PHARMACHEM LIMITED (Scrip Code: 543594) issued to Non-Promoters on a preferential basis pursuant to warrant conversion. The shares are permitted to trade on the Exchange from January 20, 2026. The shares were allotted at Rs. 13.05 per share (face value Rs. 10 plus premium of Rs. 3.05) and are subject to lock-in until July 30, 2026.

Key Points

  • 22,44,000 equity shares of Rs. 10/- each issued at premium of Rs. 3.05/-
  • Issue price: Rs. 13.05 per share
  • Issued to Non-Promoters on preferential basis pursuant to warrant conversion
  • Distinguished numbers: 24045251 to 26289250
  • New shares rank pari-passu with existing equity shares
  • ISIN: INE0MC401013
  • Scrip Code: 543594

Regulatory Changes

No regulatory changes introduced. This is a routine listing notification under existing BSE listing regulations.

Compliance Requirements

  • Trading members are informed of the new securities listing
  • Lock-in restrictions must be observed: all 22,44,000 shares (Dist. Nos. 24045251 to 26289250) are locked-in until July 30, 2026
  • Shares must be treated as pari-passu with existing equity shares for all corporate actions

Important Dates

  • Date of Allotment: November 29, 2025
  • Trading Commencement: January 20, 2026 (Tuesday)
  • Lock-in Expiry: July 30, 2026
  • Circular Date: January 19, 2026

Impact Assessment

Market Impact: Low. This represents a routine preferential allotment for a single company with no broader market implications.

Shareholder Impact: The issuance of 22,44,000 new shares will dilute existing shareholders’ holdings. The shares were issued at Rs. 13.05 per share to Non-Promoters through warrant conversion.

Trading Impact: Minimal impact on overall market trading volumes. The locked-in shares cannot be traded until July 30, 2026, limiting immediate liquidity impact.

Impact Justification

Routine new securities listing for a single company with limited market-wide impact; affects only DIPNA PHARMACHEM LIMITED shareholders and trading members.